Alzheimer's disease is classified as a progressive neurological disease that affects the functioning of the brain, ultimately leading to neuron loss. It is a neurodegenerative disease of the brain which leads to loss of memory and cognitive functions. Alzheimer's treatment is a high risk, high reward market which has a huge revenue generating potential.
Global demand for Alzheimer's Drugs is expected to witness growth in the upcoming future due to growing prevalence of the neurological disorder in the geriatric population, increasing average life span of people and the aging population. The major factor restraining the substantial growth of Alzheimer's Drugs is the lack of techniques for diagnosing or treating Alzheimer's disease.
The major factor challenging the substantial growth of Alzheimer's Drugs is the difficulty involved in the early diagnosis of indication of Alzheimer's disease. North America and Europe has the highest markets share by value in global Alzheimer's Drugs market and Asia Pacific region is projected to have a significant growth during the forecast period.
This market research report includes in depth analysis of Alzheimer's Drugs in each application and in the regional segment separately to provide in depth view of key insights and market scenario. Forecasts are also provided for all the market segments for the period 2016-2021.
- Eli Lilly
- GE Healthcare
- Bayer Pharmaceuticals
Key Topics Covered:
1. A Market Overview
2. Executive Summary
3. Market Landscape
4. Market Forces
5. Strategic Analysis
6. Alzheimer's Drugs Market - By Drug Type:
7. Alzheimer's Drugs Market - By Phase:
8. Alzheimer's Drugs Market - By Geography:
9. Market Entropy
10. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/lzx7w4/alzheimers_drugs